Madeline Nguyen, DO
Adult Medicine · Sacramento, CANPI 1316333453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $972 and has fallen 50.3% since, to $483 in 2025.
Across 209 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$658
- Pfizer$396
- Lilly USA, LLC$310
- AstraZeneca$281
- Bayer$269
- Boehringer Ingelheim$268
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $658 |
| Pfizer | 26 | $396 |
| Lilly USA, LLC | 16 | $310 |
| AstraZeneca | 12 | $281 |
| Bayer | 11 | $269 |
| Boehringer Ingelheim | 13 | $268 |
| AbbVie | 9 | $214 |
| Merck | 11 | $195 |
| GSK | 7 | $162 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $105 |
| Sanofi Pasteur Inc. | 5 | $101 |
| Hologic Sales And Service, LLC | 4 | $92 |
| Organon | 5 | $71 |
| Exact Sciences | 3 | $67 |
| Novartis | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Cranial Technologies, Inc | 4 | $58 |
| Dexcom, Inc. | 2 | $57 |
| Phadia US Inc. | 3 | $57 |
| Scilex Pharmaceuticals Inc. | 3 | $56 |
| Seqirus USA Inc | 2 | $46 |
| Amgen | 2 | $40 |
| Mannkind Corporation | 2 | $40 |
| Johnson & Johnson | 2 | $40 |
| Sobi, Inc | 2 | $33 |
| Biomarin Pharmaceutical Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 2 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Qiagen, LLC | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Bioventus LLC | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,950 in reported general payments places this provider in the 85th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $173,755 |
| JardianceEmpagliflozin | 101 | $134,750 |
| JanuviaSitagliptin Phosphate | 62 | $70,032 |
| EliquisApixaban | 45 | $48,009 |
| Nurtec OdtRimegepant Sulfate | 18 | $31,466 |
| TrulicityDulaglutide | 16 | $27,662 |
| RybelsusSemaglutide | 11 | $23,538 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $21,863 |
| LatudaLurasidone Hcl | 13 | $20,746 |
| Spiriva RespimatTiotropium Bromide | 15 | $15,622 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $15,403 |
| FarxigaDapagliflozin Propanediol | 11 | $15,216 |
| TradjentaLinagliptin | 16 | $12,631 |
| LinzessLinaclotide | 12 | $12,276 |
| Atrovent HfaIpratropium Bromide | 18 | $12,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $658 | $197,293152 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr, Tradjenta | $268 | $178,405146 claims |
| PfizerEliquis, Nurtec Odt | $396 | $79,47563 claims |
| MerckJanuvia | $195 | $70,03262 claims |
| Lilly USA, LLCTrulicity | $310 | $27,66216 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $21 | $20,74613 claims |
| GSKBreo Ellipta, Incruse Ellipta | $162 | $18,24438 claims |
| AstraZenecaFarxiga | $281 | $15,21611 claims |
| AbbVieLinzess | $214 | $12,27612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 221 adult medicine providers in California.
Other adult medicine in Sacramento
- Robert FerreraSacramento$7K
- Michael MouaSacramento$1K
- Rebecca LewisSacramento$866
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
- Patrick WelchArroyo Grande$20K
- Craig BobsonManteca$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.